

Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal)

Technology appraisal guidance

Published: 13 August 2025

www.nice.org.uk/guidance/ta1089

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments in adults. This is because Gilead has confirmed that it does not intend to make an evidence submission for the appraisal. Gilead considers that the technology is unlikely to be a cost-effective use of NHS resources.

Information

If NHS organisations wish to consider sacituzumab govitecan for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-7142-8